CLINICAL_TRIALS
trial_result
· 2013-10-17
Clinical Trial Update: BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients [Phase 2]
Summary
Phase 2 trial of afatinib (BIBW2992) in advanced EGFR-FISH positive non-small cell lung cancer has completed. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2013-10-17